Dorzagliatin - Hua Medicine

Drug Profile

Dorzagliatin - Hua Medicine

Alternative Names: HMS-5552; RO-5305552; Sinogliatin

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Hua Medicine
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Preclinical Metabolic syndrome

Most Recent Events

  • 28 Dec 2017 Preclinical trials in Metabolic syndrome (Combination therapy) in China (PO) before December 2017 (Hua Medicine pipeline, December 2017)
  • 28 Dec 2017 Preclinical trials in Type-2 diabetes mellitus (Combination therapy) in China (PO) before December 2017 (Hua Medicine pipeline, December 2017)
  • 15 Oct 2017 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in China (PO) (NCT03141073)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top